{"id":"NCT01218971","sponsor":"Alkermes, Inc.","briefTitle":"ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)","officialTitle":"A Multicenter Double-Blind Extension of Alkermes Study ALK21-003 to Evaluate the Long-Term Safety of Medisorb® Naltrexone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-08","primaryCompletion":"2004-09","completion":"2004-09","firstPosted":"2010-10-13","resultsPosted":"2010-12-08","lastUpdate":"2010-12-24"},"enrollment":332,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence"],"interventions":[{"type":"DRUG","name":"Medisorb naltrexone 190 mg","otherNames":[]},{"type":"DRUG","name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL"]}],"arms":[{"label":"Medisorb naltrexone 380 mg","type":"EXPERIMENTAL"},{"label":"Medisorb naltrexone 190 mg","type":"EXPERIMENTAL"}],"summary":"This was a Phase 3 multicenter extension of Alkermes' Study ALK21-003 (NCT01218958 \\[the base study\\]) that evaluated the safety of Medisorb® naltrexone (VIVITROL®) administered every 4 weeks for 48 weeks (13 injections) in alcohol-dependent adults who had completed Study ALK21-003.","primaryOutcome":{"measure":"Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study","timeFrame":"Up to 48 weeks (13 injections), not including base study","effectByArm":[{"arm":"Medisorb Naltrexone 380 mg","deltaMin":143,"sd":null},{"arm":"Medisorb Naltrexone 190 mg","deltaMin":130,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":175},"commonTop":["Headache NOS","Nasopharyngitis","Upper respiratory tract infection NOS","Nausea","Fatigue"]}}